The Latin American Ovarian Cancer Market size is estimated to grow at a steady rate between 2022 to 2027.
The increase in the prevalence of new ovarian cases and the rising need for more effective treatment are the major factors driving the Latin American ovarian cancer market. Also, the increasing geriatric population, rising use of new drugs and therapies, and increasing healthcare spending are expected to propel the market growth. Mutagenic alterations in the DNA are the cause of ovarian cancer. Inherited genetic abnormalities cause ovarian cancer. The risk of getting ovarian cancer is considerable if a woman has inherited mutations in the BRCA1 and BRCA2 genes.
The most common form of ovarian cancer is epithelial ovarian cancer (EOC), which arises from the epithelium of the ovary. Ovarian cancer is a kind of cancer that affects a lot of women. It kills more women than any other cancer of the female genital system, and it ranks fifth in overall cancer mortality among women. Because this kind of cancer is rarely detected early, therapy might be challenging at an advanced stage. Ovarian cancer is the seventh-commonest cancer among women. Increased cancer risk factors have resulted in an upward trend in cancer incidence throughout the world. Ovarian cancer was responsible for 4.4 percent of all cancer-related deaths among women in the recent past.
Additionally, the pharmaceutical companies in emerging countries such as Brazil and Mexico invest in the research and development of innovative products such as combination drugs to reduce manufacturing costs, improve medication concordance, reduce side effects, and increase profitability.
However, the Latin American market for ovarian cancer drugs is expected to be hindered by the growing use of biologics and targeted treatments. Targeted treatments work as drug replacements by identifying and attacking cancer cells rather than normal ones.
This research report on the Latin American ovarian cancer market has been segmented and sub-segmented into the following categories:
By Stage of Cancer:
By Cancer Type:
By Type of Treatment:
Geographically, the Latin American market is expected to account for a moderate share in the global ovarian cancer market during the forecast period. The market growth is attributed to many therapeutics in the development stage and the presence of market competition regional-wide. However, the growing geriatric population among women is a significant concern because women in this age group had the lowest survival rate; therefore, the aging population is expected to increase the market growth in the region. Drugs like Bevacizumab (Avastin) and Pazopanib (Votrient) are expected to increase the market, dominated by generics like paclitaxel and carboplatin. In addition, improving healthcare infrastructure and healthcare facilities in Latin America are further likely to influence the market growth. In Latin American regional market. The countries such as Mexico and Brazil are contributing to the regional market growth. In addition, the factors such as increasing government funding and proliferation of ovarian cases augment the market growth. Over the forecast period, Mexico has witnessed a significant share in the Ovarian Cancer Therapeutics Market owing to the rising burden of ovarian cancer and increasingly innovating and developing combination drugs to treat ovarian cancer drugs.
KEY MARKET PLAYERS:
A few of the prominent companies operating in the Latin American ovarian cancer market profiled in this report are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Genentech Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com